Global partnerships Predicine operates across Silicon Valley, Houston, Shanghai, Singapore, and Boston and collaborates with biopharma companies, institutions, and governments, presenting a broad market for CDx collaborations, co-development opportunities, and clinical trial support services.

Liquid biopsy leadership With a proprietary cell-free DNA and RNA liquid biopsy platform and a growing portfolio of blood, urine, and tissue assays, there are multiple entry points for assay partnerships, research collaborations, and platform licensing to accelerate oncology diagnostics pipelines.

NGS kit launches Recent and upcoming products such as PredicineCARE NGS Kit offer a concrete upsell path to biopharma and academic customers seeking turnkey sequencing solutions for treatment selection, monitoring, and MRD assessment.

Expansion-ready coverage Global footprint and front-line focus on precision oncology position Predicine to pursue global clinical trial support, regulatory submissions, and market access strategies with regional life sciences distributors and contract manufacturers.

Data and analytics Utilize their tech stack including SAP, IBM SPSS, OpenAI, and cloud infrastructure to propose advanced data analytics, biomarker discovery services, and real-world evidence generation to pharma partners seeking data-driven drug development insights.